A5041271928- Cytomegalovirus and herpesvirus research
- COVID-19 Clinical Research Studies
- Antifungal resistance and susceptibility
- SARS-CoV-2 and COVID-19 Research
- Transplantation: Methods and Outcomes
- Fungal Infections and Studies
- COVID-19 and healthcare impacts
- Respiratory viral infections research
- Herpesvirus Infections and Treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- Long-Term Effects of COVID-19
- Polyomavirus and related diseases
- COVID-19 Impact on Reproduction
- Immunodeficiency and Autoimmune Disorders
- Heparin-Induced Thrombocytopenia and Thrombosis
- Neutropenia and Cancer Infections
- Water Treatment and Disinfection
- Poxvirus research and outbreaks
- Hepatitis B Virus Studies
- Immunotherapy and Immune Responses
- HIV-related health complications and treatments
- Nail Diseases and Treatments
- Advanced Causal Inference Techniques
University of Miami
2017-2025
Sylvester Comprehensive Cancer Center
2020-2023
Miami Transplant Institute
2022-2023
Jackson Health System
2022-2023
Jackson Memorial Hospital
2018-2020
Abstract Background Letermovir was approved in 2017 for prevention of cytomegalovirus (CMV) infection seropositive (R+) allogeneic hematopoietic cell transplantation (HCT) patients. Post‐marketing data with this new agent are scarce. Methods We compared the incidence both CMV reactivation (any viremia) and clinically significant (CS‐CMVi; DNAemia leading to preemptive treatment or presence tissue invasive disease) at days +100 +200 post‐HCT 25 adult HCT patients who received letermovir...
Cytomegalovirus (CMV) reactivation is a major complication among seropositive allogeneic hematopoietic cell transplantation recipients; however, data on CMV after chimeric antigen receptor (CAR) T-cell therapy are limited. We report the incidence and outcomes of 95 adult CMV-seropositive patients who received CAR between February 2018 2023. were (any viremia) clinically significant infection (cs-CMV). Thirty-one (33%) had evidence viremia), 10 (11%) cs-CMV. The median time from infusion to...
One year into the pandemic, published data on hematopoietic cell transplantation (HCT) recipients with coronavirus disease 2019 (COVID-19) remain limited.
Data on severe acute respiratory distress syndrome coronavirus 2 monoclonal antibody (SARS-CoV-2-specific mAb) use in hematologic malignancy and hematopoietic cell transplantation (HM/HCT) patients are limited. Here, we describe our experience with the of casirivimab-imdevimab or bamlanivimab for treatment disease 2019 (COVID-19) HM/HCT patients.This was a retrospective chart review at University Miami Hospital Sylvester Comprehensive Cancer Center COVID-19 who received from November 21,...
Abstract We report a case of an immunocompromised man with monkeypox who experienced disease progression despite timely initiation tecovirimat and ultimately required utilization cidofovir VIGIV for treatment. In patients, might present more severe course requiring consideration alternative treatment strategies
Isavuconazole (ISA) is a newer antifungal used in patients with history of hematologic malignancies and hematopoietic transplant cellular therapies (HM/TCT). Although it has more favorable side-effect profile, breakthrough invasive fungal infections (bIFIs) while on ISA have been reported.In this single-center retrospective study evaluating HM/TCT who received prophylactic for ≥7 days, we evaluated the incidence potential risk factors bIFIs.We 106 ISA. The were predominantly male (60.4%)...
Abstract Background The optimal number of doses as well the role for measurement postvaccination titers after measles, mumps, rubella (MMR) vaccination in adult hematopoietic cell transplantation (HCT) recipients remains unknown. Methods In present study, we assessed humoral immunity against mumps and before MMR 187 adults who received at least one dose vaccine HCT. Results Among those with baseline titers, posttransplant prevaccination seroprotection rates were 56%, 30%, 54% rubella,...
Invasive aspergillosis is the most common invasive mold infection following a hematopoietic cell transplant. Widespread use of antifungal prophylaxis has led to increasing incidence cryptic Aspergillus species. calidoustus one those emerging species and notorious for multidrug resistance antifungals. Here, we report case disseminated A. in stem transplant recipient who was successfully treated with combination therapy that included novel antifungal.
Anti-rejection medications are essential in preventing organ rejection amongst solid transplant recipients; however, these agents also cause profound immunosuppression, predisposing lung recipients (LTRs) to infectious complications. The timely management including prevention, diagnosis, and treatment of such complications is vital prevent significant morbidity mortality allograft dysfunction. LTRs inundated with microbes that may be recognized as commensals hosts intact immune systems....
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been raging since the end of 2019 and shown worse outcomes in solid organ transplant (SOT) recipients. The clinical differences as well between viruses have not defined this population.This is a retrospective cohort study adult SOT recipients with nasopharyngeal swab or bronchoalveolar lavage PCR positive for either SARS-CoV-2, seasonal coronavirus, syncytial virus (RSV) influenza from January 2017 to October 2020....
Background: CAUTIs constitute forty percent of nosocomial infections, yet their direct link with mortality remains debated. In 2009, NHSN estimated the economic burden in U.S. to be over $340 million. Limited data exist on inter-physician concordance diagnosing CAUTIs, especially patients abnormal genitourinary (GU) anatomy. Our study assessed inter-provider variability CAUTI 50 such patients, including those meeting NHSN(National healthcare safety network) criteria. Methods: We included a...
Abstract Background Isavuconazole (ISA) is a relatively newer triazole with broad spectrum of anti-fungal activity and has been used for both treatment prophylaxis invasive fungal infections (IFIs) in patients hematologic malignancy (HM) hematopoietic stem cell transplant (HSCT) more favorable side-effect profile as compared to other agents. Widespread prophylactic use mold-active agents resulted decline the incidence IFIs, but breakthrough (bIFIs) reported previously. Thus, we performed...
Neurocysticercosis is a parasitosis caused by the larval stage of pork tapeworm Taenia solium. The diagnosis challenging as morphology on neuroimaging can be inconclusive and serology frequently negative. We describe case 24-year old Hispanic man who presented with seizures loss consciousness. Magnetic resonance imaging (MRI) showed cystic mass in right frontal lobe. Work-up that included body computed tomography (CT) scan Western blot for Echinococcus cysticercosis was unrevealing. He...
We report the case of a 66 year-old woman who presented nodular skin lesions on her back and upper extremities. Biopsy revealed amastigotes that were identified as Leishmania infantum-chagasi by PCR. Evaluation also showed hepatomegaly pulmonary nodules. Treatment with amphotericin B led to complete resolution lesions.
Abstract Background The opportunistic parasite Toxoplasma causes life-threatening complications in immunocompromised hosts such as hematopoietic cell transplantation (HCT) recipients. Trimethoprim-sulfamethoxazole (TMP-SMX) is the agent of choice preventing Pneumocystis jirovecii pneumonia and Toxoplasma, but bone marrow suppression often precludes its use. Broad-spectrum atovaquone also targets protozoan tachyzoite cyst forms, few studies examine efficacy prophylaxis among this vulnerable...
Severe acute respiratory syndrome coronavirus 2 is associated with severe disease in patients hematologic malignancy. We report a series of underlying malignancy and 2019 discrepancy between radiographic findings molecular testing. Initial chest x-ray should raise suspicion immunosuppressed typical clinical presentation even negative initial